期刊
BRITISH JOURNAL OF CANCER
卷 102, 期 1, 页码 162-164出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605471
关键词
PTEN; colorectal cancer; cetuximab
类别
BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n = 43) and on metastatic (n = 24) sites in CRC patients treated with cetuximab. RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001). CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised. British Journal of Cancer (2010) 102, 162-164. doi:10.1038/sj.bjc.6605471 www.bjcancer.com Published online 1 December 2009 (C) 2010 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据